Alnylam Pharmaceuticals Inc "RNAi Roundtable" Webcast Series: Patisiran & Vutrisiran, for the Treatment of Transthyretin-Mediated Amyloidosis Transcript
Good day, and welcome to the RNAi Roundtable. Today's conference is being recorded. At this time, I would like to turn the conference over to Josh Brodsky, Director of Investor Relations and Corporate Communications. Please go ahead.
Good afternoon, everyone. Thank you for joining us for today's RNAi Roundtable where we'll be discussing patisiran and vutrisiran, RNAi therapeutics in development for the treatment of ATTR amyloidosis.
I'm Josh Brodsky, Director of Investor Relations and Corporate Communications at Alnylam. With me today are Eric Green, Senior Vice President and General Manager of the TTR Program; Mike, a patient living with hereditary ATTR amyloidosis; John Vest, Executive Director of Clinical Research; and Rena Denoncourt, Senior Director and Program Leader for Vutrisiran.
Today's RNAi Roundtable is the first in a series of roundtables that we'll be hosting over the next few months to review progress across our various programs. Today
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
